Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
July 30, 2023 8:01 AM 2 min read

Trump's Legal Woes, Raskin Vs. Gosar And Van Orden's Controversy: This Week In Politics

by Benzinga Neuro Benzinga Staff Writer
Follow
FlipboardIcon version of the Flipboard logo

This week in politics was marked by a series of high-profile stories, each contributing to the ongoing narrative of a deeply divided and contentious political landscape. From legal challenges faced by former President Donald Trump to controversial remarks by lawmakers, the week was anything but quiet.

Trump’s Legal Challenges: Michael Cohen, former personal attorney to Donald Trump, expressed his belief that Trump is feeling the pressure of his numerous legal challenges. Cohen suggested that key figures like Ivanka Trump, Jared Kushner, and Mark Meadows may also be cooperating with investigations. Read the full article here.

Raskin vs. Gosar: Rep. Jamie Raskin (D-MD) strongly criticized Rep. Paul Gosar (R-AZ) for suggesting that President Joe Biden‘s National Drug Control Strategy is flawed because it doesn't mention God or faith. Raskin dismissed the idea as "preposterous." Read the full article here.

For more in-depth coverage of these stories and more, you can read more on Benzinga's politics coverage by following this link.

Photo by Frederic Legrand – COMEO on Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
NewsPoliticsGlobalGeneralDonald TrumpJamie RaskinMelania Trump
Beat the Market With Our Free Pre-Market Newsletter
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter

Melania’s Absence: Former First Lady Melania Trump has reportedly rebuffed her husband Donald Trump‘s requests to join him on the 2024 campaign trail. Melania has not publicly commented on the campaign since her single interview with Fox News in May. Read the full article here.

US-China Tensions: In response to Central Intelligence Agency (C.I.A.) director William Burns‘ statement about the agency's efforts to anticipate any attack on Taiwan, China has pledged to take countermeasures. The tension between China and the US over Taiwan has been escalating, with both sides taking a hard stance on the issue. Read the full article here.

Van Orden’s Controversy: Rep. Derrick Van Orden (R-WI) found himself in a controversy after he verbally abused a group of teenage Senate pages in the Capitol rotunda. Van Orden's outburst was met with outrage by members of the upper chamber, with Senate Majority Leader Chuck Schumer (D-NY) expressing shock at Van Orden's refusal to apologize. Read the full article here.


Engineered by Benzinga Neuro, Edited by Navdeep Yadav


The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.


Comments
Loading...